Type 2 Diabetes: GLP-1 Mounjaro May Lower Heart Attack Risk
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Type 2 Diabetes: GLP-1 Mounjaro May Lower Heart Attack Risk" is generating significant coverage in the Health category, with 8 articles from 8 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Inside Precision Medicine, tum.de, TCTMD.com and News-Medical. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 92d ago.
Quick answers
Why is "Type 2 Diabetes: GLP-1 Mounjaro May Lower Heart Attack Risk" trending?
Because 8 independent news sources published 8 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- MACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients Inside Precision Medicine · 95d ago
- Obesity drug significantly reduces the risk of serious cardiovascular events and infections tum.de · 95d ago
- Claims Data Lend Support to Tirzepatide’s CV Effects in Patients With Diabetes TCTMD.com · 95d ago
- Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes News-Medical · 95d ago
- Zepbound Lowers Heart Attack, Stroke Risk Among Type 2 Diabetics U.S. News & World Report · 95d ago
- Obesity drug significantly reduces the risk of serious cardiovascular events and infections Deutsches Zentrum für Herz-Kreislauf-Forschung · 95d ago
- GLP-1 drugs like Mounjaro may help lower heart attack risk by 33% Medical News Today · 95d ago
- Type 2 Diabetes: GLP-1 Mounjaro May Lower Heart Attack Risk Healthline · 95d ago
Topics
Related trends
World Diabetes Day 2026: Diabetes can develop silently for years: Why one simple health check could help detect the risk early and prevent future complications
World Diabetes Day 2026 highlights that diabetes often develops silently for years, with 11 million undiagnosed U.S. adults and 115.2 million with prediabetes, while guidelines now recommend blood screening for all adults by age 35.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.